Nadia Yousaf
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report.
Journal: JTO clinical and research reports
Published: March 09, 2026
Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Journal: Nature
Published: January 14, 2026
Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experience.
Journal: The British journal of radiology
Published: August 15, 2025
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 07, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2024
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitis.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: September 08, 2023
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction.
Journal: Cardio-oncology (London, England)
Published: July 29, 2022
Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib': Not looking back.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 16, 2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Journal: Cell reports. Medicine
Published: June 06, 2022
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Journal: Cancer cell
Published: April 12, 2022
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Journal: Nature
Published: March 07, 2022
Last Updated: 09/26/2026